Auburn, NY, where grit meets grind and precision never sleeps. That’s the DNA of Currier Plastics, a company that’s been molding its own future since 1982. Founded by Raymond Currier, a WWII fighter pilot turned engineer, Currier started with 2 used injection molding machines, 3 employees, and a belief that respect, for people and the process, was non-negotiable. His son, John Currier, began sweeping floors before running the business, taking over as President in 1987 at just 27. Four decades later, that same family-first philosophy is now meeting private equity horsepower.
Sheridan Capital Partners just acquired Currier Plastics on Sept 19, 2025, marking the company’s first institutional investment since day one. This isn’t just another transaction, it’s a full-circle moment for a founder-led team that scaled from a small shop to 287,000 sq. ft. of precision manufacturing muscle. Sheridan’s deal squad, Sean Dempsey, Michael Bernard, Brian McGregor & Dimitri Kallioras, played it sharp, backed by McDermott Will & Emery on legal, William Blair on advisory, and Stout Capital with Benesch, Friedlander, Coplan & Aronoff repping Currier. Clean deal, serious intent.
But the move isn’t about exit, it’s about evolution. Andrew McLean, a veteran with 25+ years in medtech & pharma manufacturing, has stepped in as CEO. McLean’s résumé reads like a tour through healthcare innovation, SteriPack, Sirtex Medical, BD, Pfizer. John Currier stays on as President, ensuring the legacy that built this house stays intact. Alongside CFO Michael Cartner & VP of New Product Development Gary Kieffer (employee #3 & co-owner), Currier’s leadership team blends deep roots with new firepower.
Currier’s pivot to healthcare now drives approximately 60% of revenue, up from a past heavy in hospitality (now less than 8%). It’s a smart play, targeting high-value segments like in-vitro diagnostics, pharma packaging & handheld medical instruments in a $23B medical injection molding market projected to reach $34B by 2032 (5.5% CAGR). The company’s expanded footprint includes a new 75,000-sq.-ft. facility with 25,000 sq. ft. of ISO Class 8 cleanroom space, built for growth, not guesswork.
With ISO 13485:2016 certification, FDA registration & an under-one-roof model covering blow molding, injection molding & final assembly, Currier is one of the few in the U.S. with this level of vertical capability. Sheridan’s backing fuels the next phase: scaling cleanroom capacity, ramping automation & pursuing strategic M&A to deepen its healthcare edge.
From 8,000 sq. ft. and a dream to 287,000 sq. ft. and national reach, Currier Plastics isn’t just manufacturing plastics, it’s molding precision into permanence. Sheridan Capital Partners just added the torque. The next era of Currier? Bigger, smarter, sharper.
